Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies

© 2019 Elsevier B.V. Cancer remains a major public health problem worldwide and was responsible for 9.6 million deaths in 2018. Oncologic treatments such as doxorubicin (Dox) and trastuzumab (Trz) are chemotherapeutic drugs used to treat several types of cancer, including solid and non-solid maligna...

Full description

Saved in:
Bibliographic Details
Main Authors: Nanthip Prathumsap, Krekwit Shinlapawittayatorn, Siriporn C. Chattipakorn, Nipon Chattipakorn
Format: Journal
Published: 2020
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075876366&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/68569
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-68569
record_format dspace
spelling th-cmuir.6653943832-685692020-04-02T15:29:42Z Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies Nanthip Prathumsap Krekwit Shinlapawittayatorn Siriporn C. Chattipakorn Nipon Chattipakorn Pharmacology, Toxicology and Pharmaceutics © 2019 Elsevier B.V. Cancer remains a major public health problem worldwide and was responsible for 9.6 million deaths in 2018. Oncologic treatments such as doxorubicin (Dox) and trastuzumab (Trz) are chemotherapeutic drugs used to treat several types of cancer, including solid and non-solid malignancies. Although these drugs have a significant impact on the reduction in mortality of cancer patients, this treatment has an adverse effect on the cardiovascular system. The mechanisms associated with Dox-induced cardiotoxicity involve inflammation, oxidative stress, apoptosis, mitochondria impairment and dysregulation of autophagy. Unfortunately, Trz, an effective anti-cancer drug, can potentiate these adverse effects. Trz is a recombinant DNA-derived humanized monoclonal antibody against human epidermal growth factor receptor 2 (HER2). Despite its high anti-cancer efficacy, Trz also has a cardiotoxic effect. Unlike Dox, this adverse effect of Trz on the heart is mostly reversible. A strategy to prevent this undesirable effect is urgently needed. Currently, several pharmacological interventions have shown promising results that might effectively attenuate Dox- and Trz-induced cardiac dysfunction. In this review, reports from in vitro, in vivo and clinical studies pertinent to the underlying mechanisms involved in chemotherapy-induced cardiotoxicity, are comprehensively summarized and discussed. In addition, the potential pharmacological interventions to prevent these cardiotoxic effects are described. 2020-04-02T15:29:42Z 2020-04-02T15:29:42Z 2020-01-05 Journal 18790712 00142999 2-s2.0-85075876366 10.1016/j.ejphar.2019.172818 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075876366&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/68569
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Pharmacology, Toxicology and Pharmaceutics
spellingShingle Pharmacology, Toxicology and Pharmaceutics
Nanthip Prathumsap
Krekwit Shinlapawittayatorn
Siriporn C. Chattipakorn
Nipon Chattipakorn
Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies
description © 2019 Elsevier B.V. Cancer remains a major public health problem worldwide and was responsible for 9.6 million deaths in 2018. Oncologic treatments such as doxorubicin (Dox) and trastuzumab (Trz) are chemotherapeutic drugs used to treat several types of cancer, including solid and non-solid malignancies. Although these drugs have a significant impact on the reduction in mortality of cancer patients, this treatment has an adverse effect on the cardiovascular system. The mechanisms associated with Dox-induced cardiotoxicity involve inflammation, oxidative stress, apoptosis, mitochondria impairment and dysregulation of autophagy. Unfortunately, Trz, an effective anti-cancer drug, can potentiate these adverse effects. Trz is a recombinant DNA-derived humanized monoclonal antibody against human epidermal growth factor receptor 2 (HER2). Despite its high anti-cancer efficacy, Trz also has a cardiotoxic effect. Unlike Dox, this adverse effect of Trz on the heart is mostly reversible. A strategy to prevent this undesirable effect is urgently needed. Currently, several pharmacological interventions have shown promising results that might effectively attenuate Dox- and Trz-induced cardiac dysfunction. In this review, reports from in vitro, in vivo and clinical studies pertinent to the underlying mechanisms involved in chemotherapy-induced cardiotoxicity, are comprehensively summarized and discussed. In addition, the potential pharmacological interventions to prevent these cardiotoxic effects are described.
format Journal
author Nanthip Prathumsap
Krekwit Shinlapawittayatorn
Siriporn C. Chattipakorn
Nipon Chattipakorn
author_facet Nanthip Prathumsap
Krekwit Shinlapawittayatorn
Siriporn C. Chattipakorn
Nipon Chattipakorn
author_sort Nanthip Prathumsap
title Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies
title_short Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies
title_full Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies
title_fullStr Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies
title_full_unstemmed Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies
title_sort effects of doxorubicin on the heart: from molecular mechanisms to intervention strategies
publishDate 2020
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075876366&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/68569
_version_ 1681426843743289344